nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—SLC12A1—Cation-coupled Chloride cotransporters—SLC12A2—skin cancer	0.0894	0.404	CbGpPWpGaD
Methyclothiazide—SLC12A3—Cation-coupled Chloride cotransporters—SLC12A2—skin cancer	0.0812	0.367	CbGpPWpGaD
Methyclothiazide—SLC12A1—appendage—skin cancer	0.0443	0.194	CbGeAlD
Methyclothiazide—Quinethazone—SLC12A2—skin cancer	0.0355	1	CrCbGaD
Methyclothiazide—CA1—nerve—skin cancer	0.0216	0.0948	CbGeAlD
Methyclothiazide—CA4—nerve—skin cancer	0.0169	0.0741	CbGeAlD
Methyclothiazide—Vasculitis—Vemurafenib—skin cancer	0.0139	0.027	CcSEcCtD
Methyclothiazide—SLC12A1—epithelium—skin cancer	0.012	0.0527	CbGeAlD
Methyclothiazide—CA2—hair follicle—skin cancer	0.0117	0.0515	CbGeAlD
Methyclothiazide—SLC12A3—female reproductive system—skin cancer	0.0117	0.0513	CbGeAlD
Methyclothiazide—Photosensitivity—Vemurafenib—skin cancer	0.0112	0.0218	CcSEcCtD
Methyclothiazide—SLC12A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.0111	0.0501	CbGpPWpGaD
Methyclothiazide—Pulmonary oedema—Imiquimod—skin cancer	0.0103	0.02	CcSEcCtD
Methyclothiazide—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.0101	0.0455	CbGpPWpGaD
Methyclothiazide—Malnutrition—Vismodegib—skin cancer	0.00962	0.0187	CcSEcCtD
Methyclothiazide—CA4—nipple—skin cancer	0.00958	0.0421	CbGeAlD
Methyclothiazide—CA4—neck—skin cancer	0.00948	0.0416	CbGeAlD
Methyclothiazide—Muscle spasms—Vismodegib—skin cancer	0.00925	0.018	CcSEcCtD
Methyclothiazide—Purpura—Imiquimod—skin cancer	0.00874	0.017	CcSEcCtD
Methyclothiazide—CA2—nipple—skin cancer	0.00795	0.0349	CbGeAlD
Methyclothiazide—CA2—neck—skin cancer	0.00786	0.0345	CbGeAlD
Methyclothiazide—Photosensitivity reaction—Vemurafenib—skin cancer	0.00779	0.0151	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00754	0.0146	CcSEcCtD
Methyclothiazide—SLC12A1—head—skin cancer	0.00744	0.0327	CbGeAlD
Methyclothiazide—Aplastic anaemia—Dactinomycin—skin cancer	0.00722	0.014	CcSEcCtD
Methyclothiazide—Decreased appetite—Vismodegib—skin cancer	0.00683	0.0133	CcSEcCtD
Methyclothiazide—Constipation—Vismodegib—skin cancer	0.00672	0.013	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Imiquimod—skin cancer	0.00664	0.0129	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Temozolomide—skin cancer	0.00653	0.0127	CcSEcCtD
Methyclothiazide—Erythema multiforme—Vemurafenib—skin cancer	0.00646	0.0125	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.00643	0.0125	CcSEcCtD
Methyclothiazide—CA1—lymphoid tissue—skin cancer	0.00636	0.0279	CbGeAlD
Methyclothiazide—CA1—female reproductive system—skin cancer	0.00613	0.0269	CbGeAlD
Methyclothiazide—Malnutrition—Vemurafenib—skin cancer	0.00595	0.0115	CcSEcCtD
Methyclothiazide—Vascular purpura—Temozolomide—skin cancer	0.00564	0.0109	CcSEcCtD
Methyclothiazide—Asthenia—Vismodegib—skin cancer	0.00564	0.0109	CcSEcCtD
Methyclothiazide—CA2—connective tissue—skin cancer	0.00563	0.0247	CbGeAlD
Methyclothiazide—Erythema multiforme—Imiquimod—skin cancer	0.00551	0.0107	CcSEcCtD
Methyclothiazide—Diarrhoea—Vismodegib—skin cancer	0.00537	0.0104	CcSEcCtD
Methyclothiazide—CA2—epithelium—skin cancer	0.00535	0.0235	CbGeAlD
Methyclothiazide—Photosensitivity—Fluorouracil—skin cancer	0.00529	0.0103	CcSEcCtD
Methyclothiazide—Purpura—Temozolomide—skin cancer	0.00524	0.0102	CcSEcCtD
Methyclothiazide—CA1—head—skin cancer	0.00512	0.0225	CbGeAlD
Methyclothiazide—CA2—skin of body—skin cancer	0.00509	0.0223	CbGeAlD
Methyclothiazide—Malnutrition—Imiquimod—skin cancer	0.00507	0.00984	CcSEcCtD
Methyclothiazide—Vomiting—Vismodegib—skin cancer	0.00499	0.00969	CcSEcCtD
Methyclothiazide—SLC12A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00496	0.0224	CbGpPWpGaD
Methyclothiazide—Rash—Vismodegib—skin cancer	0.00495	0.00961	CcSEcCtD
Methyclothiazide—Dermatitis—Vismodegib—skin cancer	0.00495	0.0096	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Vemurafenib—skin cancer	0.00485	0.00942	CcSEcCtD
Methyclothiazide—CA4—female reproductive system—skin cancer	0.00479	0.021	CbGeAlD
Methyclothiazide—Nausea—Vismodegib—skin cancer	0.00467	0.00905	CcSEcCtD
Methyclothiazide—Agitation—Imiquimod—skin cancer	0.00466	0.00904	CcSEcCtD
Methyclothiazide—CA2—mammalian vulva—skin cancer	0.00464	0.0204	CbGeAlD
Methyclothiazide—Pneumonia—Bleomycin—skin cancer	0.00464	0.009	CcSEcCtD
Methyclothiazide—SLC12A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00451	0.0203	CbGpPWpGaD
Methyclothiazide—Pneumonia—Dactinomycin—skin cancer	0.00432	0.00839	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00426	0.00827	CcSEcCtD
Methyclothiazide—Decreased appetite—Vemurafenib—skin cancer	0.00422	0.00819	CcSEcCtD
Methyclothiazide—Constipation—Vemurafenib—skin cancer	0.00415	0.00805	CcSEcCtD
Methyclothiazide—CA2—lymphoid tissue—skin cancer	0.00412	0.0181	CbGeAlD
Methyclothiazide—Pulmonary oedema—Docetaxel—skin cancer	0.00411	0.00798	CcSEcCtD
Methyclothiazide—Agranulocytosis—Dactinomycin—skin cancer	0.00401	0.00779	CcSEcCtD
Methyclothiazide—CA4—head—skin cancer	0.004	0.0176	CbGeAlD
Methyclothiazide—Photosensitivity reaction—Temozolomide—skin cancer	0.00398	0.00773	CcSEcCtD
Methyclothiazide—CA2—female reproductive system—skin cancer	0.00397	0.0175	CbGeAlD
Methyclothiazide—Anorexia—Imiquimod—skin cancer	0.00394	0.00766	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Temozolomide—skin cancer	0.00393	0.00763	CcSEcCtD
Methyclothiazide—Pneumonia—Temozolomide—skin cancer	0.00391	0.00759	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00386	0.00748	CcSEcCtD
Methyclothiazide—Body temperature increased—Vemurafenib—skin cancer	0.00384	0.00744	CcSEcCtD
Methyclothiazide—Paraesthesia—Imiquimod—skin cancer	0.00372	0.00721	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Fluorouracil—skin cancer	0.00367	0.00712	CcSEcCtD
Methyclothiazide—Erythema multiforme—Dactinomycin—skin cancer	0.00365	0.00708	CcSEcCtD
Methyclothiazide—Pneumonia—Fluorouracil—skin cancer	0.0036	0.00699	CcSEcCtD
Methyclothiazide—Decreased appetite—Imiquimod—skin cancer	0.0036	0.00698	CcSEcCtD
Methyclothiazide—CA1—lymph node—skin cancer	0.00359	0.0158	CbGeAlD
Methyclothiazide—Hypersensitivity—Vemurafenib—skin cancer	0.00358	0.00694	CcSEcCtD
Methyclothiazide—Asthenia—Vemurafenib—skin cancer	0.00348	0.00676	CcSEcCtD
Methyclothiazide—Agranulocytosis—Fluorouracil—skin cancer	0.00334	0.00649	CcSEcCtD
Methyclothiazide—Diarrhoea—Vemurafenib—skin cancer	0.00332	0.00644	CcSEcCtD
Methyclothiazide—CA2—head—skin cancer	0.00332	0.0146	CbGeAlD
Methyclothiazide—Erythema multiforme—Temozolomide—skin cancer	0.0033	0.00641	CcSEcCtD
Methyclothiazide—Urticaria—Imiquimod—skin cancer	0.00329	0.00638	CcSEcCtD
Methyclothiazide—Body temperature increased—Imiquimod—skin cancer	0.00327	0.00635	CcSEcCtD
Methyclothiazide—Leukopenia—Bleomycin—skin cancer	0.00322	0.00626	CcSEcCtD
Methyclothiazide—Dizziness—Vemurafenib—skin cancer	0.00321	0.00623	CcSEcCtD
Methyclothiazide—Vomiting—Vemurafenib—skin cancer	0.00309	0.00599	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Docetaxel—skin cancer	0.00306	0.00595	CcSEcCtD
Methyclothiazide—Rash—Vemurafenib—skin cancer	0.00306	0.00594	CcSEcCtD
Methyclothiazide—Dermatitis—Vemurafenib—skin cancer	0.00306	0.00593	CcSEcCtD
Methyclothiazide—Hypersensitivity—Imiquimod—skin cancer	0.00305	0.00592	CcSEcCtD
Methyclothiazide—Headache—Vemurafenib—skin cancer	0.00304	0.0059	CcSEcCtD
Methyclothiazide—Malnutrition—Temozolomide—skin cancer	0.00304	0.0059	CcSEcCtD
Methyclothiazide—Cramp muscle—Docetaxel—skin cancer	0.00302	0.00586	CcSEcCtD
Methyclothiazide—Leukopenia—Dactinomycin—skin cancer	0.00301	0.00584	CcSEcCtD
Methyclothiazide—Asthenia—Imiquimod—skin cancer	0.00297	0.00576	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Bleomycin—skin cancer	0.00294	0.00571	CcSEcCtD
Methyclothiazide—Nausea—Vemurafenib—skin cancer	0.00288	0.00559	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Bleomycin—skin cancer	0.00288	0.00559	CcSEcCtD
Methyclothiazide—Vision blurred—Temozolomide—skin cancer	0.00286	0.00556	CcSEcCtD
Methyclothiazide—Diarrhoea—Imiquimod—skin cancer	0.00283	0.00549	CcSEcCtD
Methyclothiazide—CA4—lymph node—skin cancer	0.0028	0.0123	CbGeAlD
Methyclothiazide—Anorexia—Bleomycin—skin cancer	0.0028	0.00544	CcSEcCtD
Methyclothiazide—Agitation—Temozolomide—skin cancer	0.00279	0.00542	CcSEcCtD
Methyclothiazide—Dizziness—Imiquimod—skin cancer	0.00274	0.00531	CcSEcCtD
Methyclothiazide—Vertigo—Temozolomide—skin cancer	0.00273	0.0053	CcSEcCtD
Methyclothiazide—Leukopenia—Temozolomide—skin cancer	0.00272	0.00528	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Dactinomycin—skin cancer	0.00268	0.00521	CcSEcCtD
Methyclothiazide—Paraesthesia—Bleomycin—skin cancer	0.00264	0.00512	CcSEcCtD
Methyclothiazide—Vision blurred—Fluorouracil—skin cancer	0.00264	0.00512	CcSEcCtD
Methyclothiazide—Vomiting—Imiquimod—skin cancer	0.00263	0.00511	CcSEcCtD
Methyclothiazide—Anorexia—Dactinomycin—skin cancer	0.00261	0.00507	CcSEcCtD
Methyclothiazide—Rash—Imiquimod—skin cancer	0.00261	0.00506	CcSEcCtD
Methyclothiazide—Dermatitis—Imiquimod—skin cancer	0.00261	0.00506	CcSEcCtD
Methyclothiazide—Pneumonia—Docetaxel—skin cancer	0.0026	0.00505	CcSEcCtD
Methyclothiazide—Headache—Imiquimod—skin cancer	0.00259	0.00503	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00256	0.00498	CcSEcCtD
Methyclothiazide—Decreased appetite—Bleomycin—skin cancer	0.00256	0.00496	CcSEcCtD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00252	0.0114	CbGpPWpGaD
Methyclothiazide—Jaundice—Docetaxel—skin cancer	0.00252	0.00489	CcSEcCtD
Methyclothiazide—Leukopenia—Fluorouracil—skin cancer	0.00251	0.00486	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Temozolomide—skin cancer	0.00248	0.00481	CcSEcCtD
Methyclothiazide—Nausea—Imiquimod—skin cancer	0.00246	0.00477	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Temozolomide—skin cancer	0.00243	0.00471	CcSEcCtD
Methyclothiazide—Agranulocytosis—Docetaxel—skin cancer	0.00241	0.00468	CcSEcCtD
Methyclothiazide—Decreased appetite—Dactinomycin—skin cancer	0.00238	0.00463	CcSEcCtD
Methyclothiazide—Anorexia—Temozolomide—skin cancer	0.00236	0.00459	CcSEcCtD
Methyclothiazide—Urticaria—Bleomycin—skin cancer	0.00234	0.00453	CcSEcCtD
Methyclothiazide—CA2—lymph node—skin cancer	0.00232	0.0102	CbGeAlD
Methyclothiazide—Body temperature increased—Bleomycin—skin cancer	0.00232	0.00451	CcSEcCtD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00229	0.0103	CbGpPWpGaD
Methyclothiazide—Anaphylactic shock—Fluorouracil—skin cancer	0.00229	0.00443	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Fluorouracil—skin cancer	0.00224	0.00434	CcSEcCtD
Methyclothiazide—Paraesthesia—Temozolomide—skin cancer	0.00223	0.00432	CcSEcCtD
Methyclothiazide—Erythema multiforme—Docetaxel—skin cancer	0.00219	0.00426	CcSEcCtD
Methyclothiazide—Anorexia—Fluorouracil—skin cancer	0.00218	0.00423	CcSEcCtD
Methyclothiazide—Body temperature increased—Dactinomycin—skin cancer	0.00217	0.00421	CcSEcCtD
Methyclothiazide—Hypersensitivity—Bleomycin—skin cancer	0.00217	0.0042	CcSEcCtD
Methyclothiazide—Decreased appetite—Temozolomide—skin cancer	0.00216	0.00418	CcSEcCtD
Methyclothiazide—Constipation—Temozolomide—skin cancer	0.00212	0.00412	CcSEcCtD
Methyclothiazide—Asthenia—Bleomycin—skin cancer	0.00211	0.00409	CcSEcCtD
Methyclothiazide—Paraesthesia—Fluorouracil—skin cancer	0.00205	0.00398	CcSEcCtD
Methyclothiazide—Malnutrition—Docetaxel—skin cancer	0.00202	0.00392	CcSEcCtD
Methyclothiazide—Hypersensitivity—Dactinomycin—skin cancer	0.00202	0.00392	CcSEcCtD
Methyclothiazide—Decreased appetite—Fluorouracil—skin cancer	0.00199	0.00385	CcSEcCtD
Methyclothiazide—Urticaria—Temozolomide—skin cancer	0.00197	0.00382	CcSEcCtD
Methyclothiazide—Asthenia—Dactinomycin—skin cancer	0.00197	0.00382	CcSEcCtD
Methyclothiazide—Body temperature increased—Temozolomide—skin cancer	0.00196	0.0038	CcSEcCtD
Methyclothiazide—Muscle spasms—Docetaxel—skin cancer	0.00194	0.00377	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—CDKN2A—skin cancer	0.0019	0.00858	CbGpPWpGaD
Methyclothiazide—Diarrhoea—Dactinomycin—skin cancer	0.00188	0.00364	CcSEcCtD
Methyclothiazide—Vomiting—Bleomycin—skin cancer	0.00187	0.00363	CcSEcCtD
Methyclothiazide—Rash—Bleomycin—skin cancer	0.00185	0.0036	CcSEcCtD
Methyclothiazide—Dermatitis—Bleomycin—skin cancer	0.00185	0.00359	CcSEcCtD
Methyclothiazide—Hypersensitivity—Temozolomide—skin cancer	0.00183	0.00355	CcSEcCtD
Methyclothiazide—Urticaria—Fluorouracil—skin cancer	0.00182	0.00352	CcSEcCtD
Methyclothiazide—Leukopenia—Docetaxel—skin cancer	0.00181	0.00351	CcSEcCtD
Methyclothiazide—Body temperature increased—Fluorouracil—skin cancer	0.00181	0.00351	CcSEcCtD
Methyclothiazide—Asthenia—Temozolomide—skin cancer	0.00178	0.00345	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—PTGS2—skin cancer	0.00178	0.00802	CbGpPWpGaD
Methyclothiazide—Nausea—Bleomycin—skin cancer	0.00175	0.00339	CcSEcCtD
Methyclothiazide—Vomiting—Dactinomycin—skin cancer	0.00174	0.00338	CcSEcCtD
Methyclothiazide—Rash—Dactinomycin—skin cancer	0.00173	0.00336	CcSEcCtD
Methyclothiazide—Diarrhoea—Temozolomide—skin cancer	0.0017	0.00329	CcSEcCtD
Methyclothiazide—Hypersensitivity—Fluorouracil—skin cancer	0.00168	0.00327	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Docetaxel—skin cancer	0.00165	0.0032	CcSEcCtD
Methyclothiazide—Dizziness—Temozolomide—skin cancer	0.00164	0.00318	CcSEcCtD
Methyclothiazide—Nausea—Dactinomycin—skin cancer	0.00163	0.00316	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Docetaxel—skin cancer	0.00161	0.00313	CcSEcCtD
Methyclothiazide—Vomiting—Temozolomide—skin cancer	0.00158	0.00306	CcSEcCtD
Methyclothiazide—Anorexia—Docetaxel—skin cancer	0.00157	0.00305	CcSEcCtD
Methyclothiazide—Rash—Temozolomide—skin cancer	0.00156	0.00303	CcSEcCtD
Methyclothiazide—Diarrhoea—Fluorouracil—skin cancer	0.00156	0.00303	CcSEcCtD
Methyclothiazide—Dermatitis—Temozolomide—skin cancer	0.00156	0.00303	CcSEcCtD
Methyclothiazide—Headache—Temozolomide—skin cancer	0.00155	0.00302	CcSEcCtD
Methyclothiazide—Dizziness—Fluorouracil—skin cancer	0.00151	0.00293	CcSEcCtD
Methyclothiazide—Paraesthesia—Docetaxel—skin cancer	0.00148	0.00287	CcSEcCtD
Methyclothiazide—Nausea—Temozolomide—skin cancer	0.00147	0.00286	CcSEcCtD
Methyclothiazide—Vomiting—Fluorouracil—skin cancer	0.00145	0.00282	CcSEcCtD
Methyclothiazide—Rash—Fluorouracil—skin cancer	0.00144	0.0028	CcSEcCtD
Methyclothiazide—Dermatitis—Fluorouracil—skin cancer	0.00144	0.00279	CcSEcCtD
Methyclothiazide—Decreased appetite—Docetaxel—skin cancer	0.00143	0.00278	CcSEcCtD
Methyclothiazide—Headache—Fluorouracil—skin cancer	0.00143	0.00278	CcSEcCtD
Methyclothiazide—Constipation—Docetaxel—skin cancer	0.00141	0.00274	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—NRAS—skin cancer	0.00138	0.00624	CbGpPWpGaD
Methyclothiazide—Nausea—Fluorouracil—skin cancer	0.00136	0.00263	CcSEcCtD
Methyclothiazide—Body temperature increased—Docetaxel—skin cancer	0.0013	0.00253	CcSEcCtD
Methyclothiazide—Hypersensitivity—Docetaxel—skin cancer	0.00122	0.00236	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—KRAS—skin cancer	0.00119	0.00537	CbGpPWpGaD
Methyclothiazide—Asthenia—Docetaxel—skin cancer	0.00118	0.0023	CcSEcCtD
Methyclothiazide—Diarrhoea—Docetaxel—skin cancer	0.00113	0.00219	CcSEcCtD
Methyclothiazide—Dizziness—Docetaxel—skin cancer	0.00109	0.00212	CcSEcCtD
Methyclothiazide—Vomiting—Docetaxel—skin cancer	0.00105	0.00203	CcSEcCtD
Methyclothiazide—Rash—Docetaxel—skin cancer	0.00104	0.00202	CcSEcCtD
Methyclothiazide—Dermatitis—Docetaxel—skin cancer	0.00104	0.00202	CcSEcCtD
Methyclothiazide—Headache—Docetaxel—skin cancer	0.00103	0.00201	CcSEcCtD
Methyclothiazide—CA1—C-MYB transcription factor network—HRAS—skin cancer	0.00101	0.00457	CbGpPWpGaD
Methyclothiazide—Nausea—Docetaxel—skin cancer	0.00098	0.0019	CcSEcCtD
Methyclothiazide—CA4—Metabolism—PLIN2—skin cancer	0.000976	0.00441	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PLIN2—skin cancer	0.000936	0.00423	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PLIN2—skin cancer	0.000897	0.00405	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CSPG4—skin cancer	0.000787	0.00355	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CSPG4—skin cancer	0.000754	0.00341	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CSPG4—skin cancer	0.000723	0.00327	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ENO2—skin cancer	0.000535	0.00241	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ENO2—skin cancer	0.000513	0.00232	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ENO2—skin cancer	0.000491	0.00222	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ERCC2—skin cancer	0.000311	0.0014	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ERCC2—skin cancer	0.000298	0.00134	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ERCC2—skin cancer	0.000285	0.00129	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PTGS2—skin cancer	0.000186	0.000841	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PTGS2—skin cancer	0.000179	0.000806	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PTGS2—skin cancer	0.000171	0.000773	CbGpPWpGaD
